Dysphagia, Oropharyngeal, Cerebral Palsy
Conditions
Brief summary
The purpose of current study is to investigate the effect of kinesio tape in children with spastic cerebral palsy having oropharyngeal dysphagia
Detailed description
The study tageted rhe children with spastic cerebral palsy from both sexes will be selected from hospital of Tanta university Inclusion criteria: 1. Age ranges from 2 to 7 years. 2. The degree of dysphagia ranges from 4 to 6 level according to functional oral intake scale (appendix II). 3. Diagnosed as spastic diplegia or quadriplegia. 4. Able to understand and follow instructions. Exclusion criteria: Children will be excluded if they have any of the following criteria: 1. Severe visual and auditory problems. 2. History of maxillary, head or neck surgical procedures. 3. Botulinum toxin treatment of upper esophageal sphincter dysfunction, esophageal dysphagia and/or gastroesophageal reflux disease during the previous six months.
Interventions
OTHERKinesio tape
Kinesiotape is applied on masseter muscle, orbi and infrahyoid muscles for facilitating suprahyoid muscle
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Intervention model description
Active Comparator: Kinesiotape Group In active group, KT was applied in masseter muscle, orbicularis oris and infrahyoid muscles for facilitating suprahyoid muscle and oral sensorimotor exercise In sham group will receive the oral sensorimotor exercise only
Eligibility
Sex/Gender
ALL
Age
2 Years to 7 Years
Healthy volunteers
No
Inclusion criteria
1. Age ranges from 3 to 7 years. 2. The degree of dysphagia ranges from 4 to 6 level according to functional oral intake scale (appendix II). 3. Diagnosed as spastic diplegia or quadriplegia. 4. Able to understand and follow instructions.
Exclusion criteria
Children will be excluded if they have any of the following criteria: 1. Severe visual and auditory problems. 2. History of maxillary, head or neck surgical procedures. 3. Botulinum toxin treatment of upper esophageal sphincter dysfunction, esophageal dysphagia and/or gastroesophageal reflux disease during the previous six months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oral motor assessment sacle | 1 month | Assessment for oral phase |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ultrasonography | 1 month | Assessment of pharangal phase |
Countries
Egypt
Contacts
Primary ContactHadeer Samy Abd elaziz
Outcome results
None listed